The purpose of this study is to determine whether pharmacologic lowering of low density
lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate
or markedly reduce the composite endpoint of incident all cause mortality, myocardial
infarction, stroke or coronary revascularization.